Fanconi anemia (FA), a rare autosomal recessive disease, frequently evolves to bone marrow failure and acute myeloid leukemia, and BMT is the treatment of choice for patients with FA. However, their exquisite hypersensitivity to DNA cross-linking agents is associated with severe complications and several investigators have been looking for the ideal preparatory regimen. We have been involved in a program of progressively decreasing doses of cyclophosphamide (CY) as conditioning therapy, in an attempt to identify the lowest dose of CY capable of maintaining the graft with minimum complications. Here, we describe our experience of allogeneic BMT offered to 16 patients with FA and an HLA-compatible sibling donor, conditioned with 100 mg/kg of CY. The actuarial survival is 88% at approximately 37 months. Mucositis у grade II was the most common complication (94%), followed by bacteremias (38%). Veno-occlusive disease and hemorrhagic cystitis did not occur. Sustained engraftment was obtained in 94% of patients, and acute and chronic GVHD was diagnosed in 13% and 7%, respectively. The lowest dose of CY for transplant in FA patients is yet to be determined, but further reductions seem possible.
Fanconi anemia (FA) is a rare autosomal recessive disease almost always linked to bone marrow failure, and evolving frequently to acute myeloid leukemia or myelodysplastic syndromes. 1 Bone marrow transplantation (BMT) has been considered the best treatment for this disorder. 2, 3 However, the cellular hypersensitivity of these patients to DNA crosslinking agents used in conditioning regimens, such as cyclophosphamide (CY) and radiotherapy, is associated with a high rate of complications and even mortality. 3, 4 The combination of radiotherapy and CY, both in low doses, has been utilized in an attempt to provide sustained engraftment with acceptable toxicity. 3, 5 However, longterm effects of radiation, particularly secondary neoplasm, has led some investigators to use CY alone in conditioning. 6, 7 In an effort to determine the lowest dose capable of maintaining the graft with the minimum complications, we have progressively decreased the dose of CY over the last 15 years with good results, 8 even considering that the best preparatory regimen has been difficult to establish, by virtue of the heterogeneity of FA patients probably related to the genetic diversity found in this disease. 9 Here, we describe clinical response, engraftment and outcome of 16 FA patients treated by BMT, after a conditioning regimen of reduced dose CY, without radiotherapy.
Patients and methods

Patients
From October 1995 to March 1998, 16 patients with FA and HLA-matched compatible sibling donors underwent BMT. Diagnosis was based on clinical features of FA and diepoxybutane-induced chromosomal breakage. 10 All patients were in the severe or moderately aplastic phase of the illness, with no clinical or hematological evidence of leukemia or myelodysplasia. Characteristics of the 16 patients are given in Table 1 . There were 10 males and six females; ages ranged from 4 to 21 years (median 7 years), interval between diagnosis and BMT was from 4 to 156 months (median 14.5 months), number of packed erythrocytes and platelets concentrates given before BMT varied from zero to 50 (median 7.5 units). All donors were tested before transplant and had no evidence of FA. Number of donor nucleated BM cells infused was considered adequate and ranged from 2.24 to 6.2 × 10 
Methods
All patients received CY 25 mg/kg once daily i.v. for 4 consecutive days (total dose 100 mg/kg). MESNA (25 mg/kg i.v. per day) was given with the CY. Patients were isolated in single rooms with high efficiency particulate air (HEPA). In the case of ABO incompatibility, red blood cells or plasma were removed by starch sedimentation. Patients seronegative for cytomegalovirus (CMV) UNP = unique patient number; WBC = white blood cells; ANC = absolute neutrophil count; Hb = hemoglobin; Transf pre BMT = number of transfusions before BMT; B = thumb abnormality; C = consanguinity; CD = cutaneous dyskeratosis; CT = cryptorchidism; E = microphthalmia; F = typical Fanconi's face; K = urinary tract abnormality; MIG = micrognathia; RA = radius abnormality; S = skin pigmentation; ST = short stature.
were transfused with CMV-negative blood or blood which had been leukadepleted. Acyclovir prophylaxis for herpes virus and trimethropim-sulfamethoxazole for Pneumocystis carinii were used in all patients along with fluconazole for fungus. Graft-versus-host disease (GVHD) prophylaxis was with cyclosporin A (CsA) and methotrexate (MTX) according to the Seattle protocol. 11 Based on our previous experience with BMT in FA, MTX was not given to patients when у grade III mucositis was observed. Acute (a)GVHD grade II to IV was defined using published criteria, and patients surviving Ͼ21 days post transplantation with engraftment were considered at risk, 12 and patients engrafted and surviving Ͼ90 days were considered at risk to chronic (c)GVHD. 13 Engraftment was defined as an ANC Ͼ0.5 × 10 9 /l for at least 2 consecutive days without growth factor and marrow cellularity Ͼ15% by day 21 after transplant with all three cell lines present. Documented donor engraftment was confirmed by ABO typing in patients with major red blood cell group differences, chromosomal analysis for sex-mismatched patient/donors pairs and PCR targeting variable number of tandem repeats (VNTR) loci. 14 
Results
Survival
As of March 1998, 14 patients were alive. The KaplanMeier 15 survival is 88%, with a median follow-up of 599 days (range 15-1071 days) (Figure 1 ). 
Conditioning-related toxicity
Among the 16 patients, the most frequent toxicity was mucositis у grade II in 15 patients (94%). Positive blood cultures were detected in six patients (38%), viral infection in two patients (13%), bronchopneumonia in two patients (13%) and necrotizing enterocolitis in one patient (6%). No patient had veno-occlusive disease or hemorrhagic cystitis.
Graft-versus-host disease
Six patients received full doses of MTX, nine received three doses and one patient received only two. Two patients had aGVHD, both grade II. One patient received full dose MTX, progressed to extensive cGVHD and is presently alive and well (UPN 746). The second patient (UPN 703) received only two doses of MTX and died on day +55 from bacterial infection.
Causes of death
Two patients died of infection followed by multiorgan failure. One patient (UPN 676) developed extensive gramnegative bronchopneumonia before engraftment, followed by acute respiratory and multiorgan failures, and death occurred at day +15. This was a 21-year-old patient, who had had established pancytopenia for 8 years, requiring multiple transfusions and androgen therapy prior to BMT. The second patient (UPN 703) developed aGVHD grade II, and had pseudomembranous colitis caused by Clostridium difficile also followed by multiorgan failure, and expired at day +55.
Current status
All 14 surviving patients have documented donor engraftment and good hematopoietic recovery. Karnofsky performance score is 100% in 13 patients and 80% in one patient (UPN 746).
Discussion
The preparatory regimen used in our study was very effective, allowing engraftment even in transfused patients, and was associated with low toxicity. The well-described toxic effects of a CY metabolite in Fanconi patients, including severe mucositis, extensive gastrointestinal lesions and hemorrhages, fluid retention, cardiac failure and hemorrhagic cystitis 16 were partially avoided with the reduced CY dose used in the present study. Mucositis was still the most frequent complication, followed by bacteremias secondary to microorganisms that are usual inhabitants of the gastrointestinal tract, and which probably reached the blood stream through mucosal barrier breakage.
Sustained engraftment occurred in all but one of our patients, who survived less than 15 days. Gluckman, 17 and Kohli-Kumar and colleagues, 18 utilizing low doses of CY combined with radiotherapy, with or without antithymocyte globulin (ATG), also experienced good engraftment. Recently, a report from the IBMTR 19 analyzed the outcome of 151 patients with FA, all of whom received HLAcompatible sibling donor BMTs. Low rates of graft failure were found with three different conditioning regimens utilizing low doses of CY plus limited field radiotherapy, with or without ATG, low doses of CY plus total body irradiation and CY (у100 mg/kg) with or without ATG with no radiotherapy. So, engraftment is not usually a problem in FA patients undergoing BMT from an HLA-matched compatible sibling donor.
The major complication after allogeneic BMT is GVHD. Toxicity from conditioning may play an important role in the pathogenesis of aGVHD, and is supposedly related to release of cytokines secondary to damage and activation of host tissue, including the intestinal mucosa and liver. 20 The incidence of GVHD in FA patients is variable, and aGVHD and cGVHD among our patients were 13% and 7%, respectively. These results are significantly better than those previously seen in our own patients treated with higher doses of CY, 8 where aGVHD and cGVHD varied from 17% to 40% and 17% to 83%, respectively. ZanisNeto et al 4 and Flowers et al 7 also reported higher rates of acute and chronic GVHD in their series, where patients received CY in doses ranging from 120 to 200 mg/kg. It is possible that less aggressive conditioning regimens resulted in less tissue damage, consequently allowing the use of more doses of MTX, as shown by the fact that 15 patients received at least three doses of this drug.
Kohli-Kumar and colleagues 18 reported absence of aGVHD and 16% of cGVHD in patients receiving lowdose CY, limited field radiotherapy and ATG as conditioning and CsA and ATG plus prednisone as immunoprophylaxis. On the other hand, Gluckman 21 reported 47% of aGVHD grade II to IV and 46% of cGVHD in patients surviving more than 120 days, with immunoprophylaxis based on CsA alone after usual conditioning with radiotherapy. ATG in conditioning reduces the probabilities of aGVHD and cGVHD 19 according to an IBMTR report. Unfortunately, however, it has been related to secondary malignancies, especially EBV-related lymphomas and solid tumors. 18 The Kaplan-Meier survival of our group is 88%, with no ATG or radiotherapy, which is similar to several published series. 4, 6, 7, 18, 19 The follow-up of these patients is not sufficiently long for a conclusive analysis. However, looking at the FA transplants performed at our Center since November 1983, late graft failure was not observed 8 and only one patient developed a secondary malignancy (carcinoma of tongue), 6 years after BMT. Recently, Deeg et al 22 concluded that a diagnosis of FA and radiotherapy as part of conditioning were risk factors for solid tumors, developing 30 to 221 months (median 99 months) post transplant. 22 Genetically, FA is a very heterogeneous disease, and it is possible that different genetic defects determine distinct sensitivity to clastogenic agents. We are some distance from an ideal conditioning regimen for all patients with FA. Nevertheless, the progressively decreasing doses of CY without radiotherapy associated with GVHD prophylaxis with CsA and MTX, have improved our results. Sustained engraftment has been achieved, the incidences of aGVHD and cGVHD have been low, but mucositis remains moderate to severe.
The lowest dose of CY for conditioning in FA patients is yet to be determined, and further dose reductions seems possible. Dokal and Roberts 23 reported one case of a FA patient conditioned with a total CY dose of 80 mg/kg and two cases conditioned with 20 mg/kg, all of whom received only CsA as prophylaxis for GVHD. Three to 5 years after transplant, they were all well and with normal blood counts. We anticipate that with CY dose reduction, toxicity will be more tolerable, permitting more effective GVHD prophylaxis, which may result in less morbidity and mortality.
